Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free CPH Stock Alerts

Cipher Pharmaceuticals (CPH) Competitors

Cipher Pharmaceuticals logo
C$16.90 -0.23 (-1.34%)
As of 07/13/2026 04:00 PM Eastern
Compare

CPH vs. CRON, DHT.UN, GUD, THCX, and TLRY

Should you buy Cipher Pharmaceuticals stock or one of its competitors? MarketBeat compares Cipher Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cipher Pharmaceuticals include Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), Knight Therapeutics (GUD), Hydropothecary (THCX), and Tilray Brands (TLRY). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Cipher Pharmaceuticals compare to Cronos Group?

Cipher Pharmaceuticals (TSE:CPH) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Cipher Pharmaceuticals has a beta of 1.153706, meaning that its share price is 15% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.126226, meaning that its share price is 13% more volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$50.94M8.42C$11.41MC$1.1914.20
Cronos GroupC$159.54M9.18-C$32.78MN/AN/A

Cipher Pharmaceuticals has a net margin of 60.82% compared to Cronos Group's net margin of -1.29%. Cipher Pharmaceuticals' return on equity of 25.69% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals60.82% 25.69% 7.90%
Cronos Group -1.29%-0.19%-3.73%

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Comparatively, 46.4% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, indicating a potential upside of 0.59%. Cronos Group has a consensus price target of C$4.75, indicating a potential upside of 21.17%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cronos Group had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Cipher Pharmaceuticals Neutral
Cronos Group Neutral

Summary

Cronos Group beats Cipher Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Cipher Pharmaceuticals (TSE:CPH) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Cipher Pharmaceuticals has a beta of 1.153706, meaning that its share price is 15% more volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.385191, meaning that its share price is 61% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 60.82% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 25.69% beat DRI Healthcare Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals60.82% 25.69% 7.90%
DRI Healthcare Trust 5.02%2.06%4.22%

Cipher Pharmaceuticals has higher earnings, but lower revenue than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$50.94M8.42C$11.41MC$1.1914.20
DRI Healthcare TrustC$163.77M6.15C$9.73M-C$0.90N/A

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 0.7% of DRI Healthcare Trust shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, DRI Healthcare Trust had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 1 mentions for DRI Healthcare Trust and 0 mentions for Cipher Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 1.58 beat Cipher Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Cipher Pharmaceuticals Neutral
DRI Healthcare Trust Very Positive

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, indicating a potential upside of 0.59%. DRI Healthcare Trust has a consensus target price of C$24.80, indicating a potential upside of 35.52%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts clearly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 10 of the 17 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Knight Therapeutics Neutral
Cipher Pharmaceuticals Neutral

23.0% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Knight Therapeutics presently has a consensus price target of C$9.50, suggesting a potential downside of 3.06%. Cipher Pharmaceuticals has a consensus price target of C$17.00, suggesting a potential upside of 0.59%. Given Cipher Pharmaceuticals' higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Knight Therapeutics has a beta of -0.206788, meaning that its share price is 121% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153706, meaning that its share price is 15% more volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Knight Therapeutics' net margin of 1.10%. Cipher Pharmaceuticals' return on equity of 25.69% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics1.10% 0.73% 0.51%
Cipher Pharmaceuticals 60.82%25.69%7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$510.45M1.88-C$30.73MC$0.06163.33
Cipher PharmaceuticalsC$50.94M8.42C$11.41MC$1.1914.20

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Cipher Pharmaceuticals (TSE:CPH) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, indicating a potential upside of 0.59%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.69% beat Hydropothecary's return on equity.

Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals60.82% 25.69% 7.90%
Hydropothecary N/A N/A N/A

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$50.94M8.42C$11.41MC$1.1914.20
HydropothecaryN/AN/AN/AN/AN/A

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company Overall Sentiment
Cipher Pharmaceuticals Neutral
Hydropothecary Neutral

Summary

Cipher Pharmaceuticals beats Hydropothecary on 8 of the 8 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

4.1% of Tilray Brands shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tilray Brands has a beta of 3.0845, meaning that its share price is 208% more volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153706, meaning that its share price is 15% more volatile than the broader market.

Tilray Brands presently has a consensus price target of C$13.30, indicating a potential upside of 111.11%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 0.59%. Given Tilray Brands' higher possible upside, research analysts clearly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to Tilray Brands' net margin of -158.75%. Cipher Pharmaceuticals' return on equity of 25.69% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-158.75% -88.06% -1.41%
Cipher Pharmaceuticals 60.82%25.69%7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray BrandsC$858.28M0.91-C$183.24M-C$14.63N/A
Cipher PharmaceuticalsC$50.94M8.42C$11.41MC$1.1914.20

In the previous week, Tilray Brands' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Tilray Brands Neutral
Cipher Pharmaceuticals Neutral

Summary

Cipher Pharmaceuticals beats Tilray Brands on 8 of the 12 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPH vs. The Competition

Export
MetricCipher PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$429.11MC$6.39BC$7.05BC$12.99B
Dividend YieldN/A2.82%2.68%6.17%
P/E Ratio14.205.0327.1536.32
Price / Sales8.421,659.36587.929.69
Price / Cash3.5310.1829.2282.29
Price / Book3.2210.9010.754.45
Net IncomeC$11.41MC$20.27BC$3.58BC$299.09M
7 Day Performance-2.48%-0.94%-2.07%-0.38%
1 Month Performance3.62%-1.21%3.31%-0.65%
1 Year Performance31.52%9.06%26.35%31.20%

Cipher Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPH
Cipher Pharmaceuticals
N/AC$16.90
-1.3%		C$17.00
+0.6%		+30.8%C$429.11MC$50.94M14.205
CRON
Cronos Group
1.8981 of 5 stars		C$4.07
+3.8%		C$4.75
+16.7%		+36.6%C$1.52BC$159.54MN/A450
DHT.UN
DRI Healthcare Trust
3.2631 of 5 stars		C$18.91
+2.2%		C$24.80
+31.1%		+31.4%C$1.04BC$163.77MN/AN/A
GUD
Knight Therapeutics
N/AC$9.84
-0.1%		C$9.50
-3.5%		+59.9%C$966.08MC$510.45M164.00725
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel